Condition: Refractory Multiple Myeloma · Sponsor: Ontario Clinical Oncology Group (OCOG)
A phase II study of single agent elranatamab in patients with relapsed and/or refractory multiple myeloma (MM) who have previously received at least three classes of therapeutic agents and are refractory to the last line of treatment. The primary objective of this study is to improve the tolerability and safety of elranatamab in patients with relapsed and/or refractory multiple myeloma by evaluating an outpatient and intermittent dosing strategy.
This description comes directly from the study's public registry record.
Emilio Aguirre, CRA,HIT,CHIM · 905-527-2299 · aguirre@mcmaster.ca
Daryl Solomon · 905-527-2299 · solomd5@mcmaster.ca
Always discuss trial participation with your own doctor first.
| Vancouver Cancer Center | Vancouver, British Columbia, Canada | Recruiting |
| Juravinski Cancer Center | Hamilton, Ontario, Canada | Recruiting |
| Kingston General Hospital | Kingston, Ontario, Canada | Recruiting |
| London Health Science Centre - Victoria Hospital | London, Ontario, Canada | Recruiting |
| London Health Science Centre - Victoria Hospital | London, Ontario, Canada | Recruiting |
| Ottawa Hospital | Ottawa, Ontario, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06421675